加科思(01167.HK)斥2,500萬美元認購Hebecell約132萬股A輪股份
加科思(01167.HK)公布,公司及9名其他投資者與Hebecell訂立購股協議,公司將以2,500萬美元認購Hebecell約132.12萬股A輪股份,佔其已發行股本約19.74%,每股購買價18.9213美元。
公司執行董事王印祥、王曉潔、胡雲雁、北京加科思前任董事林為棟及主要股東晟德大藥廠股份聯繫人Centerlab Investment等關連人士,亦有份參與此輪投資,合共認購將58.13萬股。
集團預期,將與Hebecell的專業知識及資源互補共用,通過未來潛在的合作來豐富產品管線,並擴大在腫瘤學及免疫學領域的開發計劃的涵蓋面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.